Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation
Guy Young, Anthonie W.A. Lensing, Paul Monagle, Christoph Male, Kirstin Thelen, Stefan Willmann, Joseph S. Palumbo, Riten Kumar, Ildar Nurmeev, Kerry Hege, Fanny Bajolle, Philip Connor, Hélène L. Hooimeijer, Marcela Torres, Anthony K.C. Chan, Gili Kenet, Susanne Holzhauer, Amparo Santamaría, Pascal Amédro, Jan Beyer‐Westendorf, Ida Martinelli, M. Patricia Massicotte, William T. Smith, Scott D. Berkowitz, Stephan Schmidt, Victoria Price, Martin H. Prins, Dagmar Kubitza
Topics & Concepts
RivaroxabanMedicineDosingCmaxAdverse effectTolerabilityPharmacokineticsPopulationAnesthesiaArea under the curveInternal medicineWarfarinAtrial fibrillationEnvironmental healthBlood Coagulation and Thrombosis MechanismsVenous Thromboembolism Diagnosis and ManagementHeparin-Induced Thrombocytopenia and Thrombosis